Benjamin Scirica, MD
Cardiovascular Disease · Boston, MANPI 1982664033
Payments from drug & device makers
Across 276 payments — averaging $40,956 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3.9M
- Amgen$3.8M
- Boehringer Ingelheim$3.2M
- Novo Nordisk AS$186K
- Merck$46K
- Astrazeneca UK Limited$45K
- plus $82K from 7 others
Across 50 payments — averaging $3149.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$129K
- AbbVie$28K
- Boehringer Ingelheim International GmbH$375
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 56 | $3,949,737 |
| Amgen | 18 | $3,804,802 |
| Boehringer Ingelheim | 11 | $3,190,115 |
| Novo Nordisk AS | 45 | $185,854 |
| Merck | 81 | $46,337 |
| Astrazeneca UK Limited | 3 | $45,377 |
| AbbVie | 36 | $44,400 |
| Eli Lilly | 3 | $10,825 |
| E.r. Squibb & Sons, L.L.C. | 1 | $7,000 |
| Boehringer Ingelheim International GmbH | 9 | $6,625 |
| AstraZeneca | 9 | $6,099 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 2 | $5,000 |
| Medtronic | 2 | $1,590 |
How this compares
$11,303,760 in reported general payments places this provider in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Boston
- Marc SabatineBoston$31.2M
- Stephen WiviottBoston$29.2M
- David MorrowBoston$19M
- Scott SolomonBoston$16.2M
- Paul RidkerBoston$16.2M
- Mohit JainBoston$13M
- Calum MacraeBoston$11.4M
- Robert GiuglianoBoston$10.5M
- Erin BohulaBoston$10M
- Michelle OdonoghueBoston$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.